Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,389	403	687	699	1,284	849
Market Cap Growth	106.29%	-41.27%	-1.77%	-45.56%	51.35%	84.30%
Enterprise Value	1,262	289	544	471	1,087	732
Last Close Price	5.60	1.86	3.91	3.92	7.74	5.59
PS Ratio	38.79	11.66	21.32	13.53	95.13	144.57
PB Ratio	20.17	1.44	3.08	2.77	4.54	2.78
P/TBV Ratio	-	5.23	30.84	12.45	11.89	6.86
P/FCF Ratio	-	-	-	307.85	-	-
P/OCF Ratio	-	-	-	187.79	-	-
EV/Sales Ratio	35.82	8.36	16.88	9.11	80.50	124.70
EV/FCF Ratio	-18.25	-	-	207.31	-	-
Debt / Equity Ratio	0.13	0.03	0.05	0.05	0.03	0.04
Debt / FCF Ratio	-	-	-	6.03	-	-
Asset Turnover	0.12	0.09	0.08	0.10	0.03	0.02
Quick Ratio	4.33	3.47	2.02	3.07	2.32	5.35
Current Ratio	4.50	3.65	2.14	3.16	2.37	5.66
Return on Equity (ROE)	-157.75%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%
Return on Assets (ROA)	-13.65%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%
Return on Capital (ROIC)	-27.95%	-18.58%	-18.82%	-16.61%	-31.93%	-15.35%
Return on Capital Employed (ROCE)	-25.30%	-21.60%	-25.50%	-21.50%	-38.60%	-26.40%
Earnings Yield	-16.13%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%
FCF Yield	-4.98%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%
Buyback Yield / Dilution	-25.54%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.